Pluristem - A Phase 2, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects with Intermitte

Grants and Contracts Details

StatusFinished
Effective start/end date11/1/123/31/15

Funding

  • Pluristem Therapeutics Incorporated: $8,969.00